BERLIN — German pharmaceutical company CureVac says it has enrolled the first participant in the phase 3 clinical study of its mRNA-based COVID-19 vaccine candidate. The Tuebingen-based company says the study is expected to include more than 35,000 participants at sites in Europe and Latin America.
“With the start of the pivotal Phase 2b/3 study, we have reached another important milestone in the development of our vaccine candidate, CVnCoV,” Franz-Werner Haas, the CEO of CureVac, said in a statement Monday.
The company expects first results of its phase 3 study by the end of March.
CureVac began development of its mRNA-based COVID-19 vaccine candidate last January.
Earlier studies showed that the newly developed vaccine was “generally well tolerated across all tested doses and induced strong antibody responses,” the company wrote. ”The quality of immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection.”
Another German company, BioNTech, helped develop the first vaccine approved for use in the United States, together with U.S. company Pfizer. It is also based on mRNA technology.
WASHINGTON (AP) — Anthony Fauci, former chief White House medical adviser, is expected to testify before Congress early next year as part of Republicans' yearslong investigation into the origins of COVID-19 and the U.
FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.
NEW YORK – Consul General of Greece in New York Dinos Konstantinou in collaboration with the Greek Orthodox Archdiocese of America hosted the opening reception of the moving exhibition Echoes of Asia Minor: Life, Catastrophe and Resilience on November 29 at the Consulate General of Greece in New York.
NEW YORK – The Hellenic Film Society USA presents Maria by Callas, the acclaimed documentary that tells the life story of the legendary Greek-American opera singer.
TEL AVIV, Israel (AP) — U.
TOKYO (AP) — Global leaders paid tribute to former U.
WASHINGTON (AP) — A defiant Rep.
Explore articles from the past and connect to your heritage!
Discover the benefits of a subscription including access to exclusive content, events, and more!
Have an idea for a story, or know of an event we should cover? We want to hear about it!
The National Herald is the paper of record of the Greek Diaspora community. Through independent journalism, we bring news to generations of Greek-Americans, with stories on the individual, community and international level. Visit and support our 106 year-old sister publication Εθνικός Κήρυξ.
To purchase a gift subscription, please log out of your account, and purchase the subscription with a new email ID.
Sign up to receive our daily email news briefing.
Sign up for a subscription to The National Herald,
starting as low as $1/week.
and receive more access to The National Herald
View our Terms of Service + Privacy Policy.
and receive more access to The National Herald
View our Terms of Service + Privacy Policy.
We use cookies on our site to personalize your experience, bring you the most relevant content, show you the most useful ads, and to help report any issues with our site. You can update your preferences at any time by visiting preferences. By selecting Accept, you consent to our use of cookies. To learn more about how your data is used, visit our cookie policy.
$1.09 USD
